NFKB1 and AL amyloidosis: Nevertheless, the available body of preclinical data and the encouraging initial clinical results preliminarily demonstrate that cancer-selective inhibition of the NF-κB pathway is possible and promises to provide an effective therapeutic strategy, with no preclusive toxicity, that could profoundly benefit patients with multiple myeloma and, potentially, other cancers where NF-κB is a driver of pathogenesis.